

NCT01735955 comparison:

Summary:
CHIA has 10 criteria while your personal folder has 10 criteria
Total found criteria: 0/10
Total not Found: 10/10
Total Extra: 2
This trial is INVALID



Nothing was Found



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development & Medical       │
│ Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient is currently benefiting from the treatment with nilotinib, as determined by the investigator │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol │
│ requirements                                                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Willingness and ability to comply with scheduled visits, treatment plans and any other study         │
│ procedures                                                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Written informed consent obtained prior to enrolling in roll-over study                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has been permanently discontinued from nilotinib treatment in the parent study due to        │
│ unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in  │
│ combination with another study medication and patient is still receiving combination therapy         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients who are currently receiving treatment with any medications that have the potential to       │
│ prolong the QT interval or inducing Torsade de Pointes and the treatment cannot be either safely     │
│ discontinued at least one week prior to nilotinib treatment or switched to a different medication    │
│ prior to start of nilotinib treatment and for the duration of the study                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after     │
│ conception and until the termination of gestation, confirmed by a positive hcG laboratory test       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, │
│ unless they are using highly effective methods of contraception during the study and for 30 days     │
│ after the final dose of nilotinib                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ -Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development \& Medical     │
│ Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study       │
│ -Patient is currently benefiting from the treatment with nilotinib, as determined by the             │
│ investigator -Patient has demonstrated compliance, as assessed by the investigator, with the parent  │
│ study protocol requirements -Willingness and ability to comply with scheduled visits, treatment      │
│ plans and any other study procedures -Written informed consent obtained prior to enrolling in roll-  │
│ over study                                                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ - Patient has been permanently discontinued from nilotinib treatment in the parent study due to      │
│ unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason │
│ - Patient has participated in a Novartis sponsored combination trial where nilotinib was dispensed   │
│ in combination with another study medication and patient is still receiving combination therapy      │
│ -Patients who are currently receiving treatment with any medications that have the potential to      │
│ prolong the QT interval or inducing Torsade de Pointes and the treatment cannot be either safely     │
│ discontinued at least one week prior to nilotinib treatment or switched to a different medication    │
│ prior to start of nilotinib treatment and for the duration of the study -Pregnant or nursing         │
│ (lactating) women, where pregnancy is defined as the state of a female after conception and until    │
│ the termination of gestation, confirmed by a positive hcG laboratory test. -Women of child-bearing   │
│ potential, defined as all women physiologically capable of becoming pregnant, unless they are using  │
│ highly effective methods of contraception during the study and for 30 days after the final dose of   │
│ nilotinib                                                                                            │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛